Stocks
Intra-Cellular Therapies (ITCI) EBITDA margin US GAAP (year values) |
|||||||||
| FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -1 024% | -349.0% | -105.6% | -34.2% | -17.1% | -17.1% | ||
| Changes by years, y/y, % | +252 279pp | +675pp | +243pp | +71pp | +17pp | -85.3% | |||
Intra-Cellular Therapies. EBITDA margin, %
Intra-Cellular Therapies. EBITDA margin, changes, pp
Intra-Cellular Therapies (ITCI) EBITDA margin US GAAP (quarter values) |
||||||||
| FY2023Q4 | FY2024Q1 | FY2024Q2 | FY2024Q3 | FY2024Q4 | LTM ? | |||
| EBITDA margin, % | ? | -25.8% | -14.4% | -17.1% | -22.1% | -14.6% | -17.1% | |
| Changes by years, y/y, % | +28pp | +37pp | +26pp | +1pp | +11pp | |||
| Changes by quarters, q/q, % | -2pp | +11pp | -3pp | -5pp | +7pp | |||
